文献速递泌尿男性生殖肿瘤

PEACE-1事后分析:校正阿比特龙-泼尼松交叉后de novo mCSPC的生存获益

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
PubMed 文献 · Eur J Cancer · 2025-09-27

PEACE-1为2×2析因III期试验,评估阿比特龙-泼尼松与前列腺放疗在de novo mCSPC中的影响,阿比特龙-泼尼松显著改善总生存(HR=0.82,95%CI 0.69-0.98)。本事后分析采用TSE、IPCW与RPSFTM三种方法校正进展后阿比特龙-泼尼松交叉,校正后OS的HR分别为0.82、0.75与0.79,敏感性分析校正ARPI交叉结果一致,支持 upfront 阿比特龙-泼尼松的生存获益。

要点

  • 对照组589例中183例进展后接受阿比特龙-泼尼松,交叉可能低估ITT获益。
  • RPSFTM、IPCW、TSE校正后OS的HR分别为0.79、0.75、0.82。
  • 校正ARPI交叉的敏感性分析结果一致,支持 upfront 阿比特龙-泼尼松。

核心结论

  • 本分析证实de novo mCSPC患者 upfront 使用阿比特龙-泼尼松的生存获益。

研究设计与样本

  • PEACE-1为2×2析因III期试验的事后分析,对照组589例随机患者中183例进展后接受阿比特龙-泼尼松。

主要发现

  • RPSFTM校正后OS的HR为0.79(95%CI 0.64-0.98)。
  • IPCW校正后OS的HR为0.75(95%CI 0.62-0.92)。
  • TSE校正后OS的HR为0.82(95%CI 0.67-0.98)。
  • 进展后接受阿比特龙-泼尼松者诊断时PSA更高、肿瘤负荷更大、骨转移更多,且更可能因mCSPC接受过多西他赛。
  • 生化进展是二线阿比特龙使用的危险因素。

关键数值与推荐

  • ITT分析中阿比特龙-泼尼松显著改善OS,HR=0.82(95%CI 0.69-0.98)。
  • 校正ARPI(阿比特龙-泼尼松或恩扎卢胺)交叉的敏感性分析结果一致。

临床怎么用

  • 解读PEACE-1的ITT生存获益时需考虑对照组进展后ARPI交叉对效应的稀释。
  • de novo mCSPC upfront 阿比特龙-泼尼松的生存获益在校正交叉后仍成立。

局限性

  • 本文为事后分析,三种统计方法均依赖各自假设。
  • 交叉人群基线预后更差,可能影响校正估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PEACE-1 is a 2×2 factorial phase III trial evaluating the impact of abiraterone-prednisone and prostate radiotherapy in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC). Abiraterone-prednisone significantly improved overall survival (OS) (hazard ratio (HR)= 0.82 [95 %CI, 0.69-0.98]). In the control arm, men often received an androgen receptor pathway inhibitor (ARPI) - either abiraterone-prednisone or enzalutamide - after progression to castration-resistant disease. The use of active drug beyond progression may improve post-progression survival and thereby attenuate the estimated benefit of early use of this drug in intention-to-treat analyses. METHODS: This post-hoc analysis applied three statistical methods to estimate an adjusted HR accounting for abiraterone-prednisone use beyond progression: Two-Stage Estimation (TSE), Inverse Probability of Censoring Weighting (IPCW) and Rank-Preserving Structural Failure Time Models (RPSFTM). RESULTS: Among 589 patients randomised to the control arm, 183 received abiraterone-prednisone after disease progression. Compared with patients who did not, these men had higher PSA at diagnosis, higher tumour burden, more bone metastases, and were more likely to have received docetaxel for mCSPC. Experiencing biochemical progression was found to be a risk factor for 2nd line abiraterone use. The HR for OS adjusted by RPSFTM, IPCW, and TSE were 0.79 [0.64-0.98], 0.75 [0.62-0.92], and 0.82 [0.67-0.98], respectively. Sensitivity analyses adjusting for ARPI cross-over (abiraterone-prednisone or enzalutamide) yielded consistent results. CONCLUSIONS: This analysis confirms the survival benefit related to upfront abiraterone-prednisone use for patients with de novo mCSPC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rousseau A, Karimi M, Michiels S, et al. Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. Eur J Cancer. 2025. PMID: 41045691. doi:10.1016/j.ejca.2025.116024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。